165 related articles for article (PubMed ID: 27172402)
1. BAX-BAK1-independent LC3B lipidation by BH3 mimetics is unrelated to BH3 mimetic activity and has only minimal effects on autophagic flux.
Reljic B; Conos S; Lee EF; Garnier JM; Dong L; Lessene G; Fairlie WD; Vaux DL; Lindqvist LM
Autophagy; 2016 Jul; 12(7):1083-93. PubMed ID: 27172402
[TBL] [Abstract][Full Text] [Related]
2. BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy.
Pedro JM; Wei Y; Sica V; Maiuri MC; Zou Z; Kroemer G; Levine B
Autophagy; 2015; 11(3):452-9. PubMed ID: 25715028
[TBL] [Abstract][Full Text] [Related]
3. Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak.
Lindqvist LM; Heinlein M; Huang DC; Vaux DL
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8512-7. PubMed ID: 24912196
[TBL] [Abstract][Full Text] [Related]
4. BCL2 and related prosurvival proteins require BAK1 and BAX to affect autophagy.
Lindqvist LM; Vaux DL
Autophagy; 2014 Aug; 10(8):1474-5. PubMed ID: 24991825
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.
Song T; Chai G; Liu Y; Yu X; Wang Z; Zhang Z
Br J Pharmacol; 2016 Feb; 173(3):471-83. PubMed ID: 26493374
[TBL] [Abstract][Full Text] [Related]
6. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
[TBL] [Abstract][Full Text] [Related]
7. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.
Renault TT; Elkholi R; Bharti A; Chipuk JE
J Biol Chem; 2014 Sep; 289(38):26481-26491. PubMed ID: 25096574
[TBL] [Abstract][Full Text] [Related]
8. BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.
Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Yoshiyama A; Aoyagi T; Hornicek FJ; Ichimura S
Anticancer Res; 2014 Nov; 34(11):6423-30. PubMed ID: 25368242
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis.
Remy J; Linder B; Weirauch U; Konovalova J; Marschalek R; Aigner A; Kögel D
Biochim Biophys Acta Mol Cell Res; 2019 Feb; 1866(2):175-189. PubMed ID: 30389373
[TBL] [Abstract][Full Text] [Related]
10. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.
Albershardt TC; Salerni BL; Soderquist RS; Bates DJ; Pletnev AA; Kisselev AF; Eastman A
J Biol Chem; 2011 Jul; 286(28):24882-95. PubMed ID: 21628457
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics.
Mattoo AR; Zhang J; Espinoza LA; Jessup JM
Clin Cancer Res; 2014 Nov; 20(21):5446-55. PubMed ID: 25208882
[TBL] [Abstract][Full Text] [Related]
12. Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax).
Lever JR; Fergason-Cantrell EA
Pharmacol Res; 2019 Apr; 142():87-100. PubMed ID: 30721730
[TBL] [Abstract][Full Text] [Related]
13. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells.
Huang S; Sinicrope FA
Autophagy; 2010 Feb; 6(2):256-69. PubMed ID: 20104024
[TBL] [Abstract][Full Text] [Related]
15. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics.
Karlberg M; Ekoff M; Huang DC; Mustonen P; Harvima IT; Nilsson G
J Immunol; 2010 Aug; 185(4):2555-62. PubMed ID: 20639495
[TBL] [Abstract][Full Text] [Related]
16. Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma.
Yang MC; Loh JK; Li YY; Huang WS; Chou CH; Cheng JT; Wang YT; Lieu AS; Howng SL; Hong YR; Chou AK
Int J Oncol; 2015 Mar; 46(3):1304-16. PubMed ID: 25586056
[TBL] [Abstract][Full Text] [Related]
17. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
Zhang J; Huang K; O'Neill KL; Pang X; Luo X
Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
[TBL] [Abstract][Full Text] [Related]
18. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
19. Mutation to Bax beyond the BH3 domain disrupts interactions with pro-survival proteins and promotes apoptosis.
Czabotar PE; Lee EF; Thompson GV; Wardak AZ; Fairlie WD; Colman PM
J Biol Chem; 2011 Mar; 286(9):7123-31. PubMed ID: 21199865
[TBL] [Abstract][Full Text] [Related]
20. Mcl-1 and Bcl-x
Hockings C; Alsop AE; Fennell SC; Lee EF; Fairlie WD; Dewson G; Kluck RM
Cell Death Differ; 2018 Mar; 25(4):721-734. PubMed ID: 29459767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
